Jim, your time is almost over. Cell Therapeutics is on the brink of financial ruin. I can't imagine that you have enough money to keep the business running through the end of the year, never mind repaying the millions in debt due this summer or funding new clinical trials.
On Friday, Cell Therapeutics was forced to postpone its annual shareholder meeting. You conveniently neglected to explain the reason during Friday's conference call but I'm assuming you failed, once again, to gain a quorum for the meeting. Let's hope that if shareholders do bother to participate, that they vote against the company's proposal to increase shares in the corporate treasury to 1.2 billion shares from its current ceiling of 800 million shares.
Without the extra shares, you won't be able to raise any more money. And without new cash, you won't be able to waste any more money on worthless drugs. Your days of living lavishly off the backs of shareholders will be over.
Jim, you have no credibility left. The bag of tricks is empty. I suspect that I'm not the only one who sees you as a pariah in the biotech business community. I doubt anyone respects you. I don't hear anyone rushing to your defense. Do the honorable thing for once in your career and resign as CEO of Cell Therapeutics.Do it now, please. If you do, cancer patients and investors will finally have reason to thank you. Sincerely, Adam Feuerstein
TheStreet.com -- Reported by Adam Feuerstein in Boston. Follow Adam Feuerstein on Twitter.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV